3月18日 - ** 药物开发商Vincerx Pharma VINC.O股价上涨47%至1.22美元
** VINC 正计划将 (link) 与为人工智能提供高性能计算基础设施的私营公司 QumulusAI 合并。
** 计划中的合并将使 QumulusAI 成为一家上市公司；QumulusAI 的股东将拥有合并后公司约 95% 的股份，而 VINC 的股东将拥有其余股份。
** 拟议交易对 QumulusAI 的估值约为 2.85 亿美元，对 Vincerx 的估值约为 1500 万美元
** 交易完成后，QumulusAI 将对合并后公司的管理团队和董事会拥有发言权
** 2024 年股价下跌 77.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.